Sub-optimal doses of human recombinant erythropoietin markedly lower serum ferritin.
Human recombinant erythropoietin in full dose substantially raises the haemoglobin in patients with end stage renal disease on dialysis. In lower doses no or little rise in haemoglobin is achieved but the ferritin, often very high before treatment, is disproportionately lowered. The hormone therefore may be useful in reducing iron overload in other situations.